Andrew J. Hale, MD

Here is a review of using this therapy in this patient population.

This is one of the first studies examining the effect of a dedicated postsplenectomy comprehensive clinic.

One promising proposal to greatly increase access to DAA HCV therapy is to keep this treatment with appropriately trained PCPs, in contrast with referring patients to infectious disease, gastroenterology, or hepatology subspecialists.

This In the Literature piece explores if we can mitigate some of the adverse reactions that are being seen in obese patients who receive vancomycin through AUC-dosing.

By itself, the POET trial should not fundamentally change the current approach to infective endocarditis treatment.